Unicycive Therapeutics (UNCY) AI Stock Analysis

• Market Cap: $78.06M
• Dividend Yield: N/A
• Average Volume (3M): 975.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.14
• Revenue Growth: -100.00%
• EPS Growth: 52.65%
• Country: US
• Employees: 22
• Sector: Healthcare
• Sector Strength: 60
• Industry: Biotechnology
• EPS (TTM): -0.76
• Shares Outstanding: 119,705,025
• 10 Day Avg. Volume: 492,492
• 30 Day Avg. Volume: 975,310
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 96.36
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $5.88
• Price Target Upside: 804.62% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Unicycive Therapeutics has significant financial challenges, including ongoing net losses and a reliance on debt for financing, which weigh heavily on its stock score. The technical analysis reveals a bearish trend, as the stock is trading below major moving averages. Valuation metrics further dampen the attractiveness of the stock due to negative profitability indicators. Without earnings call insights or recent corporate events to improve prospects, the overall score reflects these financial and technical weaknesses.

Positive Factors

FDA Approval

OLC's FDA approval is expected by its PDUFA date, affirming a buy recommendation.

Market Opportunity

OLC's potential to attain pricing similar to the leading branded drug in the category, Fosrenol, suggests a significant market opportunity.

Patient Satisfaction

High patient satisfaction with OLC is shown, with 98% of patients finding it easy to take and 89% expressing satisfaction.

Negative Factors

Clinical Trial Dropout

In the 80mg cohort of the SAD portion of the Phase 1 trial, four participants dropped out and it was not considered well-tolerated.

Clinical Trial Side Effects

In the MAD portion, the side effects in the 40mg cohort included headache, nausea, and vomiting. Only one participant dropped out of the study. In the 80mg cohort, four participants dropped out and it was not considered well-tolerated.

Clinical Trial Tolerability

The Phase 1 trial provides data on the tolerability and pharmacokinetics of UNI-494.

Unicycive Therapeutics Business Overview & Revenue Model

Company Description

Unicycive Therapeutics (UNCY) is a biopharmaceutical company focused on developing novel treatments for kidney diseases. The company operates within the healthcare sector, specifically targeting nephrology. Its core products include innovative therapies aimed at addressing unmet medical needs in patients suffering from chronic kidney diseases and related conditions.

How the Company Makes Money

Unicycive Therapeutics makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model primarily involves conducting research and development to bring its therapeutic products through clinical trials and eventually to market. Key revenue streams include potential sales from its approved drugs, licensing agreements, and partnerships with other pharmaceutical companies. Unicycive may also receive milestone payments and royalties from collaborations or licensing deals that leverage its proprietary technologies and drug candidates.

Unicycive Therapeutics Financial Statement Overview

Summary

Unicycive Therapeutics faces substantial financial challenges with sustained losses and cash flow issues. While the balance sheet shows minimal debt, the company's reliance on external financing and periodic equity volatility poses risks. The negative revenue trajectory and profitability margins highlight operational inefficiencies, necessitating strategic shifts to improve financial health.

Income Statement

Unicycive Therapeutics exhibits significant challenges in its income statement. The company has faced declining revenues, with a negative revenue in the TTM period, indicating possible returns or adjustments. Gross and net profit margins are also negative, reflecting substantial losses. The EBIT and EBITDA margins are negative, showing struggles with profitability, likely due to high operating expenses and cost structure issues.

Balance Sheet

The balance sheet reveals a moderate level of financial risk. While there is a positive stockholder equity in the TTM, the debt-to-equity ratio is relatively low due to minimal debt levels, which is a positive aspect. However, frequent equity fluctuations and periodic negative equity over the years indicate volatility. The equity ratio suggests that equity constitutes a significant portion of total assets, but past liabilities have been high compared to assets.

Cash Flow

Cash flow analysis shows Unicycive Therapeutics has been burning cash consistently, with negative free cash flow and operating cash flow figures. However, significant financing inflows have helped support operations, which is unsustainable long-term. The operating cash flow to net income ratio is not favorable, highlighting inefficiencies in converting income into cash.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
675.00K	951.00K	0.00	0.00	0.00
	Gross Profit
675.00K	944.00K	-1.00K	0.00	0.00
	EBIT
-20.77M	-18.05M	-8.98M	-2.02M	-1.96M
	EBITDA
-30.18M	-18.05M	-8.98M	0.00	-63.00K
	Net Income Common Stockholders
-30.54M	-18.06M	-10.63M	-2.51M	-2.30M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.70M	455.00K	16.58M	0.00	15.00K
	Total Assets
14.19M	2.82M	18.74M	204.00K	19.00K
	Total Debt
811.00K	155.00K	306.00K	2.51M	460.00K
	Net Debt
-8.89M	-300.00K	-16.27M	2.51M	445.00K
	Total Liabilities
18.00M	3.28M	2.26M	2.88M	903.00K
	Stockholders Equity
-3.81M	-466.00K	16.48M	-2.67M	-884.00K
Cash Flow		Free Cash Flow
-18.30M	-15.65M	-5.80M	-1.46M	-1.18M
	Operating Cash Flow
-18.28M	-15.65M	-5.77M	-1.46M	-1.18M
	Investing Cash Flow
-12.00K	-2.00K	-29.00K	0.00	0.00
	Financing Cash Flow
27.54M	-471.00K	22.38M	1.44M	1.17M

Unicycive Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UNCY, the sentiment is Positive. The current price of 0.65 is above the 20-day moving average (MA) of 0.60, above the 50-day MA of 0.59, and above the 200-day MA of 0.53, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 60.60 is Neutral, neither overbought nor oversold. The STOCH value of 64.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UNCY.

Unicycive Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.35B	3.83	-41.61%	2.85%	17.10%	1.22%
IMAB	45 Neutral	$74.52M	―	-22.38%	―	―	―
SGMT	44 Neutral	$117.48M	―	-36.92%	―	-100.00%	-12.66%
ADVM	42 Neutral	$72.91M	―	-144.41%	―	-72.22%	51.40%
TCRX	39 Underperform	$90.55M	―	-65.08%	―	-86.62%	―
ADAG	36 Underperform	$72.08M	―	-55.14%	―	-99.43%	-69.40%
UNCY	28 Underperform	$78.06M	―	-2355.27%	―	-100.00%	52.65%